 Tucked in its Q2 earnings release, Qualigen Therapeutics Inc NASDAQ: QLGN announced deprioritizing the QN-165 COVID-19 program, sending shares to fall to a 52-week low. In July, the Company filed an FDA Investigational New Drug IND application to commence Phase 1b2a clinical studies with QN-165 in hospitalized COVID-19 patients. 